A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia

被引：0
|
作者：
Absalon, Michael J. [1 ]
Breese, Erin H. [1 ]
Lee, Lynn [1 ]
O'Brien, Maureen M. [1 ]
Phillips, Christine L. [1 ]
Burns, Karen [1 ]
Mizukawa, Benjamin [1 ]
An, Qi [2 ]
Mangino, Jennifer [1 ]
Kaplan, Joel [3 ]
Norris, Robin [1 ]
Perentesis, John Peter [1 ]
机构：
[1] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA
[2] Jazz Pharmaceut, Palo Alto, CA USA
[3] Levine Childrens Hosp, Carolinas Med Ctr, Charlotte, NC USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-119618
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
336
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase II trial of CPX-351 (cytarabine:daunorubicin) liposome injection in patients with acute myeloid leukemia >60 years of age who have not been treated with intensive chemotherapy.
    Ritchie, Ellen K.
    Lee, Sangmin
    Desai, Pinkal M.
    Ball, Jeff
    Samuel, Michael S.
    Curcio, Tania
    Miah, Sumaiya
    Roboz, Gail J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [22] CPX-351 with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase Ib Study
    Bataller, Alex
    Bazinet, Alexandre
    Borthakur, Gautam
    Short, Nicholas J.
    Jabbour, Elias
    Takahashi, Koichi
    Daver, Naval
    Issa, Ghayas C.
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    BLOOD, 2023, 142
  • [23] Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial
    Medeiros, Bruno C.
    Lancet, Jeffrey E.
    Cortes, Jorge E.
    Newell, Laura F.
    Lin, Tara L.
    Ritchie, Ellen K.
    Stuart, Robert K.
    Strickland, Stephen A.
    Hogge, Donna
    Solomon, Scott R.
    Stone, Richard M.
    Bixby, Dale L.
    Kolitz, Jonathan E.
    Schiller, Gary J.
    Wieduwilt, Matthew J.
    Ryan, Daniel H.
    Hoering, Antje
    Chiarella, Michael T.
    Louie, Arthur C.
    Uy, Geoffrey L.
    BLOOD, 2016, 128 (22)
  • [24] First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
    Feldman, Eric J.
    Lancet, Jeffrey E.
    Kolitz, Jonathan E.
    Ritchie, Ellen K.
    Roboz, Gail J.
    List, Alan F.
    Allen, Steven L.
    Asatiani, Ekatherine
    Mayer, Lawrence D.
    Swenson, Christine
    Louie, Arthur C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) : 979 - 985
  • [25] Phase Ib/II Study of CPX-351 Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Bharathi, Vanthana
    Bataller, Alex
    Bazinet, Alexandre
    Borthakur, Gautam
    Jabbour, Elias
    Daver, Naval
    Short, Nicholas J.
    Takahashi, Koichi
    Issa, Ghayas C.
    Dinardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Montalban-Bravo, Guillermo
    Wierda, William G.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    BLOOD, 2024, 144 : 4272 - 4274
  • [26] A Phase I Study of CPX-351 in Combination with Busulfan and Fludarabine Conditioning and Allogeneic Stem Cell Transplantation in Adult Patients with Refractory Acute Leukemia
    Gergis, Usama
    Roboz, Gail
    Shore, Tsiporah
    Ritchie, Ellen
    Mayer, Sebastian
    Wissa, Usama
    McKenna, Marshall
    Christos, Paul
    Pearse, Roger
    Mark, Tomer
    Scandura, Joseph
    van Besien, Koen
    Feldman, Eric
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (07) : 1040 - 1045
  • [27] Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial
    Lancet, Jeffery
    Uy, Geoffrey L.
    Cortes, Jorge
    Newell, Laura F.
    Lin, Tara L.
    Ritchie, Ellen
    Stuart, Robert
    Strickland, Stephen
    Hogge, Donna
    Solomon, Scott R.
    Stone, Richard M.
    Bixby, Dale L.
    Kolitz, Jonathan E.
    Schiller, Gary J.
    Wieduwilt, Matthew J.
    Ryan, Daniel H.
    Hoering, Antje
    Chiarella, Michael
    Louie, Arthur C.
    Medeiros, Bruno C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S31 - S32
  • [28] A Phase 3 Study of CPX-351 versus Conventional 7+3 Cytarabine and Daunorubicin: Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t)
    Lin, Tara L.
    Wieduwilt, Matthew J.
    Newell, Laura F.
    Schiller, Gary J.
    Rubenstein, S. Eric
    Stock, Wendy
    Warlick, Erica
    Bixby, Dale L.
    Podoltsev, Nikolai
    An, Qi
    Faderl, Stefan
    Louie, Arthur C.
    Uy, Geoffrey L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S208 - S208
  • [29] Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias
    Feldman, Eric J.
    Lancet, Jeffrey
    Kolitz, Jonathan E.
    Ritchie, Ellen
    List, Alan F.
    Asatiani, Ekatherine
    Curcio, Tania J.
    Burton, Michelle
    Fricano, Marge
    Swenson, Christine
    Mayer, Lawrence D.
    Louie, Arthur C.
    BLOOD, 2008, 112 (11) : 1025 - 1025
  • [30] Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial
    Lancet, Jeffrey E.
    Hoering, Antje
    Uy, Geoffrey L.
    Cortes, Jorge E.
    Newell, Laura F.
    Lin, Tara L.
    Ritchie, Ellen K.
    Stuart, Robert K.
    Strickland, Stephen A.
    Hogge, Donna
    Solomon, Scott R.
    Stone, Richard M.
    Bixby, Dale L.
    Kolitz, Jonathan E.
    Schiller, Gary J.
    Wieduwilt, Matthew J.
    Ryan, Daniel H.
    Chiarella, Michael T.
    Louie, Arthur C.
    Medeiros, Bruno C.
    BLOOD, 2016, 128 (22)
12345